Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NPR3 | P17342 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246155 | 1.00 | EPHX2 (0.64) | EPHX2CYP2C9NPR3CYP2C19CTSS | |
| SCHEMBL2246160 | 1.00 | EPHX2 (0.64) | EPHX2CYP2C9NPR3CYP2C19CTSS | |
| SCHEMBL2241509 | 0.90 | EPHX2 (0.77) | EPHX2CYP2C9CTSSCTSKTAAR1 | |
| SCHEMBL2241518 | 0.90 | EPHX2 (0.77) | EPHX2CYP2C9CTSSCTSKTAAR1 | |
| SCHEMBL2241513 | 0.90 | EPHX2 (0.77) | EPHX2CYP2C9CTSSCTSKTAAR1 | |
| SCHEMBL2676303 | 0.82 | EPHX2 (0.76) | EPHX2CYP2C9NPR3CYP2C19 | |
| SCHEMBL2676298 | 0.82 | EPHX2 (0.76) | EPHX2CYP2C9NPR3CYP2C19 | |
| SCHEMBL2244134 | 0.80 | TAAR1 (0.49) | EPHX2TAAR1NPC1RAB9A | |
| SCHEMBL2244129 | 0.80 | TAAR1 (0.49) | EPHX2TAAR1NPC1RAB9A | |
| SCHEMBL2238840 | 0.78 | EPHX2 (1.00) | EPHX2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994317-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100069391-A1 | Novel sEH Inhibitors and Their Use | SMITHKLINE BEECHAM CORPORATION | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069391-A1 | Novel sEH Inhibitors and Their Use | FAH, NCEH1, SELENOI | EPHX2 16/4885CYP2C9 543/4885NPR3 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.